Testing a new medication for spine arthritis

Plain-English translation of NCT07133633 on ClinicalTrials.gov ↗ · Source last updated May 2026 · Translation generated June 2026 · How we translate trials

Phase 2 — Testing in a bigger group (up to a few hundred people) to see if the treatment actually works and is still safe.

What is this trial?

This study is testing a new medication called to see if it can help people with radiographic axial spondyloarthritis—a type of arthritis that mainly affects the spine and causes pain and stiffness. Researchers will compare different doses of the medication against a placebo (a dummy pill with no active drug) over 16 weeks, and then follow participants for up to 2 years to see how well and how safely this treatment works.

Many people with spine arthritis don't respond well enough to current treatments like NSAIDs or other biologics, or they can't tolerate them. This study is testing whether this new medication could be a better option for those patients.

Do you qualify?

You likely qualify if…

you have been diagnosed with axial spondyloarthritis and meet official classification criteria, with back pain lasting at least 3 months that started before age 45
you have X-ray evidence of ankylosing spondylitis as confirmed by a central radiologist
your disease is currently active at the time of screening
you have not responded well to or cannot tolerate NSAIDs, or you have tried at most 2 other biologic medications without success or due to side effects

You likely don't qualify if…

you were diagnosed with any form of arthritis before age 17
you have or have had cancer in the past 5 years (except non-melanoma skin cancer or certain cervical cancers that were fully removed)
you currently have an active infection
you are allergic or sensitive to tulisokibart or any of its ingredients

What participation looks like

You will be randomly assigned to receive either the new medication at one of three doses or a placebo pill for 16 weeks. After that initial period, all participants will move into a longer follow-up phase lasting up to 2 years, during which those who received lower doses or placebo may be switched to a higher dose of the medication. Throughout the study, you'll have clinic visits to check how well the treatment is working, assess any side effects, and have blood tests or imaging performed as needed.

AI-generated summary from trial data · Jun 2, 2026 · Not medical advice

Testing a new medication for spine arthritis

What is this trial?

Do you qualify?

What participation looks like

Trial locations(100 sites)